Investigating how immune cells affect treatment resistance in advanced prostate cancer
The Role of Myeloid-Derived Suppressor Cells in Resistance to Bipolar Androgen Therapy in Patients with Advanced Prostate Cancer
This study is looking at how certain immune cells in your blood might affect how well Bipolar Androgen Therapy works for men with advanced prostate cancer, with the goal of finding ways to make treatments more effective for those who struggle to respond.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10810695 on NIH RePORTER |
What this research studies
This research focuses on understanding how myeloid-derived suppressor cells (MDSCs) influence the effectiveness of Bipolar Androgen Therapy (BAT) in patients with advanced prostate cancer. The approach involves analyzing blood samples from patients before and after BAT to observe changes in immune cell populations. By identifying the role of these immune cells, the research aims to improve treatment outcomes for patients who may not respond well to current therapies. The study builds on previous findings that suggest a link between immune responses and treatment efficacy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with advanced prostate cancer who are undergoing or have undergone Bipolar Androgen Therapy.
Not a fit: Patients with early-stage prostate cancer or those not receiving Bipolar Androgen Therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for advanced prostate cancer, enhancing patient responses to therapy.
How similar studies have performed: Previous research has shown promising results with similar immune-targeted therapies, indicating potential for success in this novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Sanin Pena, David Esteban — Johns Hopkins University
- Study coordinator: Sanin Pena, David Esteban
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.